Literature DB >> 20497594

Renal function and thromboprophylaxis in critically ill patients.

Gareth M Scholey, Anton G Saayman, Christopher D Hingston, Matt P Wise.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20497594      PMCID： PMC2911697          DOI： 10.1186/cc8985

Source DB:  PubMed          Journal:  Crit Care        ISSN： 1364-8535            Impact factor:   9.097


× No keyword cloud information.
  10 in total

1.  Glomerular hyperfiltration and albuminuria in critically ill patients.

Authors:  O Fuster-Lluch; M Gerónimo-Pardo; R Peyró-García; M Lizán-García
Journal:  Anaesth Intensive Care       Date:  2008-09       Impact factor: 1.669

2.  Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.

Authors:  L Bara; A Planes; M M Samama
Journal:  Br J Haematol       Date:  1999-02       Impact factor: 6.998

3.  The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.

Authors:  Donald F Brophy; Marcus E Carr; Erika J Martin; Jürgen Venitz; Todd W B Gehr
Journal:  J Clin Pharmacol       Date:  2006-08       Impact factor: 3.126

4.  Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin.

Authors:  A J Mayr; M Dünser; S Jochberger; D Fries; A Klingler; M Joannidis; W Hasibeder; Wolfgang Schobersberger
Journal:  Thromb Res       Date:  2002-02-01       Impact factor: 3.944

5.  Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Authors:  Wendy Lim; Francesco Dentali; John W Eikelboom; Mark A Crowther
Journal:  Ann Intern Med       Date:  2006-05-02       Impact factor: 25.391

Review 6.  Comparative pharmacokinetics of LMWHs.

Authors:  M M Samama; G T Gerotziafas
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

7.  Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial.

Authors:  Sian Robinson; Aleksander Zincuk; Thomas Strøm; Torben Bjerregaard Larsen; Bjarne Rasmussen; Palle Toft
Journal:  Crit Care       Date:  2010-03-18       Impact factor: 9.097

8.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.

Authors:  Isabelle Mahé; Manvel Aghassarian; Ludovic Drouet; Claire Bal Dit-Sollier; Karine Lacut; Jean-Jacques Heilmann; Dominique Mottier; Jean-François Bergmann
Journal:  Thromb Haemost       Date:  2007-04       Impact factor: 5.249

10.  Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.

Authors:  James Douketis; Deborah Cook; Maureen Meade; Gordon Guyatt; William Geerts; Yoanna Skrobik; Martin Albert; John Granton; Paul Hébert; Guiseppe Pagliarello; John Marshall; Robert Fowler; Andreas Freitag; Christian Rabbat; David Anderson; Nicole Zytaruk; Diane Heels-Ansdell; Mark Crowther
Journal:  Arch Intern Med       Date:  2008-09-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.